Importantly, our studies show that it is feasible to target the crosstalk between the tumor microenvironment and BCP-ALL cells via carbohydrate-lectin interactions, and show that Gal3 inhibition could be a novel approach to treat BCP-ALL. This evidence concerns the gene LGALS3 and neoplasm.